Biogen shuns Plegridy premium in favor of 'sensible' pricing
This article was originally published in Scrip
Executive Summary
Biogen Idec has priced its injectable multiple sclerosis drug Plegridy (peginterferon beta-1a) in the US and Germany at a price comparable to that of its predecessor, Avonex (interferon beta-1a). The move has been praised by analysts as "sensible."